Results 11 to 20 of about 913,703 (307)

Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa

EClinicalMedicine, 2020
Background: Implementation of onchocerciasis elimination programmes has been delayed in Central Africa because of the risk of ivermectin-related serious adverse events (SAEs) in individuals with high Loa loa microfilarial densities (MFD).
Cédric B. Chesnais, Sébastien D. Pion, Charlotte Boullé, Jacques Gardon, Nathalie Gardon-Wendel, Joël Fokom-Domgue, Joseph Kamgno, Michel Boussinesq   +7 more
doaj   +1 more source

Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD

Vaccines, 2023
The disease burden of yellow fever virus infection (YFV) is quite high in the tropics where vaccination coverage is low. To date, vaccination is the most effective control strategy to mitigate and eliminate the burden of YF disease.
Flora de Andrade Gandolfi, Cassia Fernanda Estofolete, Marcia Catelan Wakai, Andreia Francesli Negri, Michela Dias Barcelos, Nikos Vasilakis, Mauricio Lacerda Nogueira   +6 more
doaj   +1 more source

The short-term and long-term adverse effects of melatonin treatment in children and adolescents: a systematic review and GRADE assessmentResearch in context

EClinicalMedicine, 2023
Summary: Background: Currently, melatonin is used to treat children and adolescents with insomnia without knowing the full extent of the short-term and long-term consequences.
Mina Nicole Händel, Henning Keinke Andersen, Anja Ussing, Anne Virring, Poul Jennum, Nanette Mol Debes, Torben Laursen, Lone Baandrup, Christina Gade, Jette Dettmann, Jonas Holm, Camilla Krogh, Kirsten Birkefoss, Simon Tarp, Mette Bliddal, Henriette Edemann-Callesen   +15 more
doaj   +1 more source

Regular treatment with formoterol for chronic asthma: serious adverse events [PDF]

, 2012
Epidemiological evidence has suggested a link between beta(2)-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe ...
Altman, Blauw, Cates, Cates, Cates, Cates, Ducharme, Greenstone, Higgins, Lipworth, Nelson, Ni Chroinin, Ni Chroinin, Pearce, Pearce, Salpeter, Walters, Walters   +17 more
core   +1 more source

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events [PDF]

, 2012
An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews.ObjectivesWe set out to compare the risks of mortality and non-fatal serious adverse events in ...
Altman, Blauw, Cates, Cates, Cates, Cates, Cates, Ducharme, Giembycz, Greenstone, Lipworth, Nelson, Ni Chroinin, Ni Chroinin, Pearce, Salpeter, Sears, Walters, Walters   +18 more
core   +1 more source

Generic versus brand-name drugs used in cardiovascular diseases [PDF]

, 2016
This meta-analysis aimed to compare the efficacy and adverse events, either serious or mild/moderate, of all generic versus brand-name cardiovascular medicines.
Boccia, Stefania, D'Andrea, Elvira, Flacco Maria, Elena, Ioannidis John, Pa, Manzoli, Lamberto, Marzuillo, Carolina, Panic, Nikola, Ricciardi, Walter, Siliquini, Roberta, Villari, Paolo   +9 more
core   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Aalbers, Aalbers, Altman, Barnes, Beach, Bleecker, Busse, Cates, Cates, Cates, Cates, Cates, Dahl, Ducharme, Ducharme, Ducharme, Giembycz, Higgins, Lasserson, Lipworth, Nelson, Ni Chroinin, Papi, Ringdal, Salpeter, Tamminen, Walters, Walters   +27 more
core   +2 more sources

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis

Frontiers in Immunology, 2023
IntroductionImmune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence exists on the treatment-related severe adverse events (SAEs) and fatal adverse ...
Yao-Ning Feng, Guang-Yu Xie, Li Xiao, Dun-Chang Mo, Jian-Feng Huang, Peng-Hui Luo, Xiu-Juan Liang   +6 more
doaj   +1 more source

Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (Review) [PDF]

, 2009
Background Epidemiological evidence has suggested a link between beta2-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are ...
Cates, CJ, Jaeschke, R, Lasserson, TJ
core   +1 more source

Clinical trials facing “Serious Adverse Events” during the ongoing COVID-19 pandemic

Indian Journal of Medical and Paediatric Oncology, 2020
Aims and Objectives: The ongoing COVID-19 pandemic is having a profound impact on the current clinical trials. We wanted to document the extent of the disruption amongst Indian clinical trial sites.
Purvish M Parikh, Prashant Mehta, Krishna Kumar MVT, K Govind Babu   +3 more
doaj   +1 more source